This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2006 Feb 16;354(7):758-60.

doi: 10.1056/NEJMe058307.

Autoimmunity and immunotherapy for cancer

Henry Koon, Michael Atkins

PMID: 16481646
DOI: 10.1056/NEJMe058307

Editorial

Autoimmunity and immunotherapy for cancer

Henry Koon et al. N Engl J Med. 2006.

. 2006 Feb 16;354(7):758-60.

doi: 10.1056/NEJMe058307.

Authors

Henry Koon, Michael Atkins

PMID: 16481646
DOI: 10.1056/NEJMe058307

No abstract available

PubMed Disclaimer

Comment on

Prognostic significance of autoimmunity during treatment of melanoma with interferon.
Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Gogas H, et al. N Engl J Med. 2006 Feb 16;354(7):709-18. doi: 10.1056/NEJMoa053007. N Engl J Med. 2006. PMID: 16481638 Clinical Trial.

Similar articles

Prognostic significance of autoimmunity during treatment of melanoma with interferon.
Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Gogas H, et al. N Engl J Med. 2006 Feb 16;354(7):709-18. doi: 10.1056/NEJMoa053007. N Engl J Med. 2006. PMID: 16481638 Clinical Trial.
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM; EORTC Melanoma Group and the Nordic Melanoma Group. Bouwhuis MG, et al. J Natl Cancer Inst. 2009 Jun 16;101(12):869-77. doi: 10.1093/jnci/djp132. Epub 2009 Jun 9. J Natl Cancer Inst. 2009. PMID: 19509353
Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R. Satzger I, et al. Int J Cancer. 2007 Dec 1;121(11):2562-6. doi: 10.1002/ijc.22951. Int J Cancer. 2007. PMID: 17680564
Adjuvant therapy for melanoma: a surgical perspective.
Sondak VK, Gonzalez RJ, Kudchadkar R. Sondak VK, et al. Surg Oncol Clin N Am. 2011 Jan;20(1):105-14. doi: 10.1016/j.soc.2010.09.001. Surg Oncol Clin N Am. 2011. PMID: 21111961 Review.
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM. Hauschild A, et al. Cancer. 2008 Mar 1;112(5):982-94. doi: 10.1002/cncr.23251. Cancer. 2008. PMID: 18236459 Review.

See all similar articles

Cited by

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.
Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, Lichty BD, Wan Y. Bridle BW, et al. Mol Ther. 2013 Apr;21(4):887-94. doi: 10.1038/mt.2012.265. Epub 2013 Jan 8. Mol Ther. 2013. PMID: 23295947 Free PMC article.
Chronic inflammatory demyelinating polyneuropathy associated with metastatic malignant melanoma of unknown primary origin.
Palma JA, Martín-Algarra S. Palma JA, et al. J Neurooncol. 2009 Sep;94(2):279-81. doi: 10.1007/s11060-009-9848-x. Epub 2009 Mar 6. J Neurooncol. 2009. PMID: 19266164
Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12.
Santini SM, Lapenta C, Donati S, Spadaro F, Belardelli F, Ferrantini M. Santini SM, et al. PLoS One. 2011 Feb 28;6(2):e17364. doi: 10.1371/journal.pone.0017364. PLoS One. 2011. PMID: 21387004 Free PMC article.
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB. Kaufman HL, et al. Nat Rev Clin Oncol. 2013 Oct;10(10):588-98. doi: 10.1038/nrclinonc.2013.153. Epub 2013 Aug 27. Nat Rev Clin Oncol. 2013. PMID: 23982524
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC.
Ricciuti B, Naqash AR, Naidoo J, Sehgal K, Miller A, Kehl K, Venkatraman D, Sands J, Lamberti G, Recondo G, Zhang J, Macherla S, Baig S, Walker P, Rangachari D, Gainor JF, Costa DB, Rizvi N, Sholl LM, Nishino M, Henick B, Farago AF, Awad MM. Ricciuti B, et al. JTO Clin Res Rep. 2020 Jul 15;1(4):100074. doi: 10.1016/j.jtocrr.2020.100074. eCollection 2020 Nov. JTO Clin Res Rep. 2020. PMID: 34589955 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information